Physician profile
Mark W Lischner
NPI 1710924188
$11,211.80
in general payments reported to CMS, 2019-2025
55 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,730 · 2020: $2,601 · 2021: $3,273 · 2022: $2,145 · 2023: $393 · 2024: $68.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $438.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,867.51 | 2019-2023 | Stiolto Respimat, Ofev |
| Glaxosmithkline, LLC. | $1,705.03 | 2019-2023 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $1,137.45 | 2019-2023 | |
| Viiv Healthcare Company | $441.29 | 2021-2024 | Dovato, Cabenuva, Rukobia |
| Grifols USA, LLC | $375.15 | 2019-2022 | |
| Gilead Sciences, INC. | $371.15 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $349.95 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $348.58 | 2020-2023 | Glassia |
| Merck Sharp & Dohme LLC | $339.92 | 2019-2023 | Dificid, Pifeltro, Delstrigo |
| Abbvie INC. | $308.87 | 2021-2022 | |
| Janssen Biotech, INC. | $295.54 | 2019-2022 | |
| Astellas Pharma US INC | $284.68 | 2019-2022 | |
| Harmony Biosciences LLC | $263.00 | 2020-2022 | |
| United Therapeutics Corporation | $241.29 | 2019-2022 | |
| Insmed, INC. | $238.32 | 2019-2022 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Lischner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.